Eye Health Academy - Eye Health Academy

Eye Health Academy Hero

Improving Clinical
Decision Making with
Engaging CME, Tools,
& Resources

Improving Clinical
Decision Making with
Engaging CME, Tools,
& Resources

Popular

Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
CME/CE
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
0.25 credits
- Carl Regillo, MD
- Jennifer I. Lim, MD, FARVO
0.25 credits
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
CME/CE
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
1.00 credit
- Arshad M. Khanani, MD, MA
- Theodore Leng, MD, MS
1.00 credit
A Closer Look at Real-World Strategies for Treatment-Resistant DME
A Closer Look at Real-World Strategies for Treatment-Resistant DME
MinuteCE®
A Closer Look at Real-World Strategies for Treatment-Resistant DME
1.00 program credit
- Durga Borkar, MD, MMCi
- Christina Y. Weng, MD, MBA, FASRS
1.00 program credit
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
MinuteCE®
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
1.00 program credit
- Jayanth Sridhar, MD
- Sabin Dang, MD
1.00 program credit
Real-World Outcomes with Durable Treatments for Retinal Diseases
Real-World Outcomes with Durable Treatments for Retinal Diseases
MinuteCE®
Real-World Outcomes with Durable Treatments for Retinal Diseases
1.00 program credit
- Christina Y. Weng, MD, MBA, FASRS
- Durga Borkar, MD, MMCi
1.00 program credit
Clinical Evidence for Durable Treatment of nAMD
Clinical Evidence for Durable Treatment of nAMD
MinuteCE®
Clinical Evidence for Durable Treatment of nAMD
1.00 program credit
- Sabin Dang, MD
- Jayanth Sridhar, MD
1.00 program credit
MinuteCE®
Reducing Retina Treatment Burden in the Real World: Emerging Evidence with Treatment Advances
1.00 credit 9 episodes
- Durga Borkar, MD, MMCi
- Christina Y. Weng, MD, MBA, FASRS
- Jayanth Sridhar, MD
- Sabin Dang, MD
1.00 credit 9 episodes
Reconsidering the Algorithm: nAMD
Reconsidering the Algorithm: nAMD
MinuteCE®
Reconsidering the Algorithm: nAMD
1.00 program credit
- Sabin Dang, MD
- Jayanth Sridhar, MD
1.00 program credit

Clinical Practice

Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
CME/CE
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
1.00 credit
- Arshad M. Khanani, MD, MA
- Karl Csaky, MD, PhD
- Christina Y. Weng, MD, MBA, FASRS
1.00 credit
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
CME/CE
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
0.50 credits
- Durga Borkar, MD, MMCi
- Diana Do, MD
- Peter K. Kaiser, MD
0.50 credits
Reconsidering the Algorithm: Treatment-Resistant DME
Reconsidering the Algorithm: Treatment-Resistant DME
MinuteCE®
Reconsidering the Algorithm: Treatment-Resistant DME
1.00 program credit
- Durga Borkar, MD, MMCi
- Christina Y. Weng, MD, MBA, FASRS
1.00 program credit
Advances in Glaucoma Treatment: Novel Topical Therapies
Advances in Glaucoma Treatment: Novel Topical Therapies
MinuteCE®
Advances in Glaucoma Treatment: Novel Topical Therapies
1.00 program credit
- Qi Cui, MD, PhD
1.00 program credit
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 1)
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 1)
MinuteCE®
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 1)
1.00 program credit
- Qi Cui, MD, PhD
1.00 program credit
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 2)
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 2)
MinuteCE®
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 2)
1.00 program credit
- Qi Cui, MD, PhD
1.00 program credit
Advances in Glaucoma Treatment: MIGS (Part 1)
Advances in Glaucoma Treatment: MIGS (Part 1)
MinuteCE®
Advances in Glaucoma Treatment: MIGS (Part 1)
1.00 program credit
- Davinder S. Grover, MD, MPH
1.00 program credit
Lessening Glaucoma Treatment Burden: Clinical Cases (Part 1)
Lessening Glaucoma Treatment Burden: Clinical Cases (Part 1)
MinuteCE®
Lessening Glaucoma Treatment Burden: Clinical Cases (Part 1)
1.00 program credit
- Qi Cui, MD, PhD
1.00 program credit